Haleon posted a higher pretax profit for 2024 despite lower revenue, and said it expected further organic revenue and profit growth this year. The consumer-health giant, which was spun out of GSK ...

HSBC analyst Jeremy Fialko downgraded Haleon (HLN) to Hold from Buy with a 420 GBp price target See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...

February 27, 2025 Sensodyne maker Haleon says 2025 revenue growth skewed to second half British consumer healthcare group Haleon on Thursday said 2025 revenue and profit growth would be weighted ...

Shares of Haleon PLC HLN advanced 2.52% to £3.94 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.41% to 8,768.01.

O n Tuesday, Jefferies reiterated its Buy rating on Haleon PLC (HLN:LN) (NYSE: HLN), maintaining a price target of GBP4.50. Currently trading at $9.20, InvestingPro analysis suggests the stock is ...

Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion.

In this article, we are going to take a look at where Haleon plc (NYSE:HLN) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care ...

British consumer healthcare group Haleon disappointed investors on Thursday after the Sensodyne toothpaste maker said 2025 revenue growth would be weighted to the second half of the year ...